Trial Profile
A Phase IIA, Open-label Study Designed to Evaluate Efficacy and Safety of BL-8040 Followed by Anti-Thymocyte Globulin (hATG), Cyclosporine and Methylprednisolone in Adult Subjects With Aplastic Anemia (AA) or Hypoplastic Myelodysplastic Syndrome (MDS)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 31 Dec 2020
Price :
$35
*
At a glance
- Drugs Motixafortide (Primary) ; Antithymocyte globulin; Ciclosporin; Methylprednisolone; Prednisone
- Indications Aplastic anaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors BioLineRx
- 28 Dec 2020 Status changed from recruiting to completed.
- 17 Jun 2018 Interim results (n=8) presented at the 23rd Congress of the European Haematology Association
- 16 Aug 2017 Planned End Date changed from 1 Jan 2018 to 1 Apr 2018.